JPWO2020210308A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210308A5 JPWO2020210308A5 JP2021559883A JP2021559883A JPWO2020210308A5 JP WO2020210308 A5 JPWO2020210308 A5 JP WO2020210308A5 JP 2021559883 A JP2021559883 A JP 2021559883A JP 2021559883 A JP2021559883 A JP 2021559883A JP WO2020210308 A5 JPWO2020210308 A5 JP WO2020210308A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- diseases
- pharmaceutically acceptable
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- -1 Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010054793 Arterial fibrosis Diseases 0.000 claims 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000024691 pancreas disease Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 201000002327 urinary tract obstruction Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831753P | 2019-04-10 | 2019-04-10 | |
| US62/831,753 | 2019-04-10 | ||
| PCT/US2020/027203 WO2020210308A1 (en) | 2019-04-10 | 2020-04-08 | Small molecule inhibitors of galectin-3 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022527395A JP2022527395A (ja) | 2022-06-01 |
| JPWO2020210308A5 true JPWO2020210308A5 (https=) | 2023-04-17 |
| JP2022527395A5 JP2022527395A5 (https=) | 2023-04-17 |
| JP7577682B2 JP7577682B2 (ja) | 2024-11-05 |
Family
ID=70476468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559883A Active JP7577682B2 (ja) | 2019-04-10 | 2020-04-08 | ガレクチン－３の低分子阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12269819B2 (https=) |
| EP (1) | EP3953349A1 (https=) |
| JP (1) | JP7577682B2 (https=) |
| KR (1) | KR102890853B1 (https=) |
| CN (1) | CN113710665A (https=) |
| WO (1) | WO2020210308A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| EP4010348B1 (en) | 2019-08-09 | 2023-12-20 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| JP7604457B2 (ja) | 2019-08-15 | 2024-12-23 | イドルシア・ファーマシューティカルズ・リミテッド | ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体 |
| CA3148365A1 (en) | 2019-08-29 | 2021-03-04 | Martin Bolli | Alpha-d-galactopyranoside derivatives |
| EP4149939A1 (en) * | 2020-05-11 | 2023-03-22 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| ES3014851T3 (en) | 2020-10-06 | 2025-04-25 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides |
| KR20230104190A (ko) * | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체 |
| KR20230145111A (ko) | 2021-02-09 | 2023-10-17 | 이도르시아 파마슈티컬스 리미티드 | 히드록시헤테로시클로알칸-카르바모일 유도체 |
| PL4301748T3 (pl) * | 2021-03-03 | 2025-09-08 | Idorsia Pharmaceuticals Ltd | Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| US9021050B2 (en) | 2012-08-31 | 2015-04-28 | Yume, Inc. | Network service system and method with off-heap caching |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| JP6904906B2 (ja) | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| JP6844991B2 (ja) | 2015-11-10 | 2021-03-17 | サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． | ジッパーを有する伸縮性衣類の製法 |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US20200061095A1 (en) * | 2017-05-12 | 2020-02-27 | Galectin Sciences, Llc | Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
-
2020
- 2020-04-08 EP EP20722856.0A patent/EP3953349A1/en active Pending
- 2020-04-08 WO PCT/US2020/027203 patent/WO2020210308A1/en not_active Ceased
- 2020-04-08 KR KR1020217036227A patent/KR102890853B1/ko active Active
- 2020-04-08 CN CN202080027684.8A patent/CN113710665A/zh active Pending
- 2020-04-08 JP JP2021559883A patent/JP7577682B2/ja active Active
- 2020-04-08 US US17/601,942 patent/US12269819B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6294277B2 (ja) | Ｈｅｃ１活性の調節因子およびそのための方法 | |
| JP2021169467A5 (https=) | ||
| JP2020510664A5 (https=) | ||
| JP2019034943A5 (https=) | ||
| JP2016517432A5 (https=) | ||
| JP7577682B2 (ja) | ガレクチン－３の低分子阻害剤 | |
| JP2014193925A5 (https=) | ||
| JP2019504898A5 (https=) | ||
| JPWO2020210308A5 (https=) | ||
| IL276654B2 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| JP2010530881A5 (https=) | ||
| ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
| JPWO2020123827A5 (https=) | ||
| CN113710276A (zh) | 苯二氮䓬衍生物作为rsv抑制剂 | |
| AU2019269409A1 (en) | Matrix metalloproteinase (MMP) inhibitors and methods of use thereof | |
| JP2012526766A5 (https=) | ||
| JP2025160175A5 (https=) | ||
| JP2009501745A5 (https=) | ||
| JP2021528451A5 (https=) | ||
| JPWO2019126085A5 (https=) | ||
| JP2018532786A5 (https=) | ||
| WO2007002637B1 (en) | N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| RU2017145086A (ru) | Производные 3-(6-хлор-3-оксо-3,4-дигидро-(2h)-1,4-бензоксазин-4-ил)пропионовой кислоты и их применение в качестве ингибиторов kmo | |
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JP2010505869A5 (https=) |